glp-1 drugs companies Market Overview: Agonists and the Obesity Market | Blog 2025’s Breakthrough GLP-1 Obesity Treatments:

Strategies to facilitate medication adherence, persistence and treatment intensification in people with T2D should be made a priority in order to achieve and maintain glycaemic targets and improve outcomes in this population

FDA-Approved Indications GLP-1 agonists (also known as GLP-1 receptor agonists, incretin mimetics, or GLP-1 analogs) represent a class of medications used to treat T2DM and, in some cases,

Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF

however, GLP-1 receptor agonists were associated with a higher risk of discontinuation of endoscopy, possibly owing to a higher risk of retained gastric content

Agents that agonize glucagon-like peptide 1 receptors, including those that co-agonize other anorexigenic hormone receptors, lead to substantial weight loss and benefits in people with varying obesity-related complications, with further trials underway